Compare Neurocrine Biosciences Inc (NBIX) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while abrdn Physical Palladium Shares ETF trades at $24.47. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | PALL | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $185.50 | $37.18 |
52-Week Low | $123.10 | $20.97 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
PALL, the Aberdeen Physical Palladium Shares ETF, trades at $24.43, down 3.48% over 24 hours. Technical indicators are bearish, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a potential buying opportunity due to supply risks and industrial demand.
The outlook for PALL hinges on palladium's supply-demand dynamics and broader commodity trends. Investment opportunities exist if palladium prices rebound from support levels, but risks include continued commodity volatility and macroeconomic pressures affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
